Dolores Baksh is Innovation Leader for the Cell Therapy Technologies business at GE Healthcare Life Sciences. In this role, Dolores works with the business functions, R&D, product management and commercial sales, to address the rapid technology development needs in the Cell Therapy field and drive innovative solutions to meet customer needs. Prior to joining GE, Dolores was Head of R&D at Organogenesis Inc., where she built and led a team of talented scientists and engineers that developed the company’s product pipeline through innovation, process development activities and business development & licensing opportunities. Dolores played an integral role in the development and approval of GINTUIT™ – the first allogeneic cell therapy product approved by CBER FDA. She was also responsible for all aspects of commercial cell manufacturing operations of commercial products. Dolores completed a Postdoctoral Fellowship at the National Institutes of Health and completed her undergraduate and doctorate degrees at the University of Toronto’s Department of Chemical Engineering and Applied Chemistry and the Institute of Biomaterials and Biomedical Engineering. Dolores is a member of the Science & Technology Committee at the Alliance for Regenerative Medicine (ARM) and a member of the ISCT – Commercialization Committee.